The PTPN22 susceptibility risk variant is not associated with the rate of joint destruction in anti-citrullinated protein antibody-positive rheumatoid arthritis.
van Nies
J A B
JA
Knevel
R
R
Daha
N
N
van der Linden
M P M
MP
Gregersen
P K
PK
Kern
M
M
le Cessie
S
S
Houwing-Duistermaat
J J
JJ
Huizinga
T W J
TW
Toes
R E M
RE
van der Helm-van Mil
A H M
AH
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000235:genetics*; D001323:Autoantibodies / Q000097:blood*; D015331:Cohort Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D010456:Peptides, Cyclic / Q000276:immunology*; D054596:Protein Tyrosine Phosphatase, Non-Receptor Type 22 / Q000235:genetics*
D001323:Autoantibodies; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; C516765:PTPN22 protein, human; D054596:Protein Tyrosine Phosphatase, Non-Receptor Type 22
Ann Rheum Dis. 2007 Dec;66(12):1604-9
17472988
Arthritis Rheum. 2005 Sep;52(9):2948-50
16145680
Arthritis Rheum. 2009 Aug;60(8):2242-7
19644859
Am J Hum Genet. 2004 Aug;75(2):330-7
15208781
Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S100-5
14969059
Ann Rheum Dis. 2008 Mar;67(3):358-63
17666451
Arthritis Rheum. 2007 Aug;56(8):2549-56
17665434
Ann Rheum Dis. 2008 Feb;67(2):251-5
17666450